+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dilated Cardiomyopathy Therapeutics: Global Strategic Business Report

  • PDF Icon

    Report

  • 197 Pages
  • April 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5140340

Global Dilated Cardiomyopathy Therapeutics Market to Reach $485.3 Million by 2030

The global market for Dilated Cardiomyopathy Therapeutics estimated at US$347 Million in the year 2022, is projected to reach a revised size of US$485.3 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2022-2030. Angiotensin II Receptor Blockers (ARBs), one of the segments analyzed in the report, is projected to record 4.9% CAGR and reach US$234.2 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Beta-Blockers segment is readjusted to a revised 4.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $102.4 Million, While China is Forecast to Grow at 4% CAGR

The Dilated Cardiomyopathy Therapeutics market in the U.S. is estimated at US$102.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$85.2 Million by the year 2030 trailing a CAGR of 4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.2% and 3.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Select Competitors (Total 47 Featured) -

  • Array BioPharma, Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Vericel Corporation

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and the publisher's Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Dilated Cardiomyopathy Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Dilated Cardiomyopathy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Aldosterone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Aldosterone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Aldosterone Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Angiotensin-Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Angiotensin-Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Angiotensin-Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Angiotensin II Receptor Blockers (ARBs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Angiotensin II Receptor Blockers (ARBs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Angiotensin II Receptor Blockers (ARBs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Beta-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 16: World Dilated Cardiomyopathy Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 18: USA Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 19: USA 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • CANADA
  • Table 20: Canada Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 21: Canada Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 22: Canada 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • JAPAN
  • Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 23: Japan Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 24: Japan Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 25: Japan 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • CHINA
  • Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 26: China Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 27: China Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 28: China 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • EUROPE
  • Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 29: Europe Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Dilated Cardiomyopathy Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 31: Europe 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 32: Europe Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 33: Europe Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 34: Europe 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • FRANCE
  • Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 35: France Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 36: France Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 37: France 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • GERMANY
  • Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 38: Germany Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: Germany Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 40: Germany 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • ITALY
  • Table 41: Italy Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 42: Italy Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 43: Italy 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 44: UK Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 45: UK Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 46: UK 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 47: Rest of Europe Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 48: Rest of Europe Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 49: Rest of Europe 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Dilated Cardiomyopathy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 50: Asia-Pacific Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 51: Asia-Pacific Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 52: Asia-Pacific 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
  • REST OF WORLD
  • Table 53: Rest of World Recent Past, Current & Future Analysis for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 54: Rest of World Historic Review for Dilated Cardiomyopathy Therapeutics by Drug Class - Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 55: Rest of World 16-Year Perspective for Dilated Cardiomyopathy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Angiotensin II Receptor Blockers (ARBs), Beta-Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors and Aldosterone Antagonists for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Array BioPharma, Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Vericel Corporation

Table Information